Biostate.AI Investment Memo

Confidential

Introduction

Biostate AI is building the first end-to-end platform for scalable precision medicine, combining ultra-low-cost multiomics (DNA + RNA sequencing) with a proprietary AI scientist (K-Dense).

Like AWS for biological data + AI, Biostate enables large-scale generation and analysis of human molecular data — unlocking faster drug discovery, better diagnostics, and truly personalized healthcare.

Investment Highlights

Here's why we think Gleamr is a strong investment candidate:

• $100B+ market opportunity: Precision medicine, multiomics, and AI-driven diagnostics
• Breakthrough technology: 10–80× cheaper DNA/RNA sequencing (from ~$3,000 to <$50)
• Category-defining AI: K-Dense outperforms leading AI models in biomedical tasks
• Strong validation: 20+ hospital partnerships (Harvard, MD Anderson, Cornell)
• Proven founder: Previously built $100M+ funded genomics company with $20M+ revenue
• Global scale from day one: US, China, India, Middle East operations
• $20M+ raised: Backed by Accel and top-tier investors

Team

Our team has deep, relevant experience in biotech, AI, and global healthcare.

• David Zhang, Ph.D, Co-founder & CEO. Former founder/CEO of a $100M+ funded genomics company with $20M+ revenue; 60+ publications, 40+ patents
• Jeremy Sobotta, CFO. Former public-company CFO; led $4B+ in biotech and medtech M&A
• Kutapa Muthanna, CEO India. Former Director at KPMG; 20+ years in finance and healthcare systems
• Zoe Zheng, CEO China. Former VC at Matrix Partners & Gaorong; deep biotech investing experience
• Mohammad Alkheilewi, CEO MENA. Former leader at Eurofins and Saudi Ministry of Health
• Advisors: Harvard, MIT, MD Anderson, Yale, and other leading institutions

Problem

Modern medicine is fundamentally inefficient:

• Drug development takes billions of dollars and years, yet benefits <20% of patients
• Treatments are designed for the “average patient,” not individuals
• Multiomics data (DNA/RNA) is:
  • Too expensive
  • Too sparse
  • Too complex for existing AI systems

As a result, precision medicine reaches <5% of the global population.

Solution

Introducing Biostate AI — a full-stack platform for scalable precision medicine.

Benefits for healthcare & pharma:

• Lower cost: Multiomics tests at a fraction of current prices
• Better insights: AI-driven biological discovery
• Faster development: Accelerated drug discovery timelines

Benefits for patients:

• More accurate diagnoses
• Personalized treatments
• Improved health outcomes and lifespan

Product

How our platform works:

For hospitals / researchers:

• Run RNA and DNA tests at dramatically reduced cost
• Generate large-scale patient molecular data
• Integrate with clinical workflows

For pharma / biotech:

• Analyze datasets using K-Dense AI
• Identify biomarkers and therapeutic targets
• Improve R&D success rates

Core components:

• RNA sequencing (BIRT + PERD)
• DNA sequencing (MARE)
• K-Dense AI scientist platform

Competition

We compete across genomics, diagnostics, and AI drug discovery.

We win on cost, scale, and intelligence:

• 10–80× cheaper sequencing
• Only integrated AI + multiomics platform
• Global clinical data advantage

Like AWS vs. legacy IT, we expect to win through infrastructure + scale + data network effects.

Business Model

Simple and scalable:

• RNA test: ~$80 per sample
• DNA test: ~$125 per sample
• 70%+ gross margins

Future expansion:

• AI licensing to pharma
• Drug discovery partnerships
• Clinical SaaS tools
• Direct-to-consumer testing

Market Sizing

We're targeting a massive and growing market:

• $70B+ U.S. cancer diagnostics market
• $100B+ global precision medicine market

Bottom-up:

• Millions of diagnostic tests annually
• Recurring testing revenue
• Expansion across multiple disease areas

Traction

Strong early validation:

• $1M+ revenue in the last 12 months
• 20+ clinical partnerships globally
• Active programs across:
  • Cancer
  • Autoimmune disease
  • Cardiovascular disease
• Backed by leading VCs and global operators

Growth Strategy

Here's how Biostate will scale:

Data acquisition

• Expand hospital partnerships globally
• Increase test volume across disease areas

AI advantage

• Continuously improve K-Dense with proprietary datasets

Commercial expansion

• Enter pharma partnerships
• Launch enterprise AI tools
• Expand into DTC (long-term)

Product Roadmap

Here's how we'll maintain and extend our product lead.

• 2023: Company founded; initial platform development
• 2024: Multiomics deployment + early partnerships
• 2025: AI scaling + global expansion
• 2026+: Pharma integration + DTC preparation

Financials

Biostate is an early but rapidly scaling platform:

• Revenue: $1M+ (last 12 months)
• Gross margin: 80%+
• Strong unit economics driven by low-cost infrastructure

Long-term:

• High-margin, data-driven platform business
• Significant operating leverage

Funding

We're raising [$X] on a SAFE. We have [$Y] committed, so [$Z] remaining.

Prior Funding

• $20M+ raised from leading global venture capital firms including Accel, Matter Venture Partners, Vision Plus Capital, InfoEdge Ventures, and Caltech Fund
• Backed by prominent individual investors including Dario Amodei (Anthropic), Emily Leproust (Twist Bioscience), and Prasad Chintamaneni
• Launched core multiomics + AI platform
• Established 20+ clinical partnerships with leading institutions including Harvard Medical School, MD Anderson, and Cornell
• Generated $1M+ revenue in the last 12 months

Current Raise

• Raising via crowdfunding (Wefunder) to expand investor base and strategic network
• $XXK committed by XXX and XXX.

Investment Highlights Recap

• $100B+ market opportunity
• Breakthrough cost advantage in sequencing
• Proprietary AI scientist platform
• Strong clinical traction and partnerships
• Proven founder and global team
• Backed by top-tier investors

Contact

David Zhang, Co-founder & CEO
contact@biostate.ai · LinkedIn